|
|
|
|
|
|
|
|
|
29.09.26 - 11:00
|
AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows (SCMP)
|
|
|
Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm's flagship cancer drug, while a new deal from US giant Merck further underscored the sector's global momentum amid easing fears of US curbs.
AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akeso's immunotherapy drug ivonescimab outside China.
Summit and AstraZeneca would......
|
|
|
|
|
|
|
28.09.26 - 23:51
|
More Hospitals Are Being Bought By Private Equity; Here′s How It′s Changing Healthcare... (ZeroHedge)
|
|
|
More Hospitals Are Being Bought By Private Equity; Here's How It's Changing Healthcare...
Authored by Lawrence Wilson and Sylvia Xu via The Epoch Times,
There's a greater than one in 10 chance your hospital is owned by someone who's trying to double their money in seven years.
If you live in Kentucky, your chances are one in six. In New Mexico, more than one in three.
Walk into an emergency room, and there's a 40 percent chance the doctor who stitches you up works for a staffing company owned by private investors, not the hospital.
At a time when less than half of Americans report being consistently able to afford healthcare, private investors are looking to hospitals and physician practices as a source of profit.
Private equity firms, which invest money on behalf of pension funds, universities, sovereign wealth funds, and wealthy individuals, buy healthcare providers expecting them to produce a better return than the stock market.
That may be no surprise to the 82 million Americans who ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.09.26 - 05:45
|
Pressestimme: ′Rhein-Zeitung′ zu Krankenkassen-Reform (DPA-AFX)
|
|
|
KOBLENZ (dpa-AFX) - "Rhein-Zeitung" zu Krankenkassen-Reform:"Für Kassenpatienten mit gutem Einkommen wird es im neuen Jahr ein böses Erwachen geben: Hunderte Euro mehr müssen sie für Kranken- und Pflegeversicherung ausgeben. Warkens - sinnvolles - Konzept ......
|
|
|
|
|
|
|
|
|
26.09.26 - 03:00
|
China′s biotech firms move up value chain as drug deals evolve beyond licensing: analysts (SCMP)
|
|
|
Chinese biotech deal making is moving beyond the licensing of individual drug candidates, as the country transforms from a follower to a global innovation leader, according to analysts.
The latest transaction underscores that shift. Beijing-based cancer drug developer InnoCare Pharma said on Thursday that it had entered into a strategic research collaboration and licensing agreement with US pharmaceutical giant Eli Lilly that could be worth up to US$3.35 billion.
InnoCare said it would use its......
|
|
|
26.09.26 - 01:48
|
Wall Street Week | China′s Trade Reckoning, Syracuse′s Second Chance, Humanoids in Healthcare (Bloomberg)
|
|
|
This week, Council on Foreign Relations President Michael Froman breaks down China's export machine, why twenty years of US pressure hasn't worked, and what happens next. And, can a $100 billion Micron factory transform Syracuse from a Rust Belt cautionary tale into a potential model for American reindustrialization? Plus, a bridge named for a hockey legend was meant to strengthen the supply chain between the US and Canada, but the neighbors can't agree on their trade relationship. Later, with 760,000 care aide openings expected every year in the US and a $400 billion long-term care bill, humanoid robots are an early bet on technology filling the care gap. (Source: Bloomberg)...
|
|